Sugi Predict

Sugi Predict / Targets / BTK

BTK

Tyrosine-protein kinase BTK · Q06187 · BTK on Sugi Atlas →

347,478 patent compounds predicted against BTK, 201,635 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL102343 SCHEMBL102343 1.00 20/20
SCHEMBL104216 SCHEMBL104216 1.00 20/20
SCHEMBL108070 SCHEMBL108070 1.00 20/20
SCHEMBL122287 SCHEMBL122287 1.00 20/20
SCHEMBL123056 SCHEMBL123056 1.00 20/20
SCHEMBL123062 SCHEMBL123062 1.00 20/20
SCHEMBL123348 SCHEMBL123348 1.00 20/20
SCHEMBL123555 SCHEMBL123555 1.00 20/20
SCHEMBL123628 SCHEMBL123628 1.00 20/20
SCHEMBL124412 SCHEMBL124412 1.00 20/20
SCHEMBL124442 SCHEMBL124442 1.00 20/20
SCHEMBL103134 SCHEMBL103134 0.87 20/20
SCHEMBL123341 SCHEMBL123341 0.86 20/20
SCHEMBL124479 SCHEMBL124479 0.85 20/20
SCHEMBL122264 SCHEMBL122264 0.85 20/20
SCHEMBL104236 SCHEMBL104236 0.84 20/20
SCHEMBL105668 SCHEMBL105668 0.83 20/20
SCHEMBL123881 SCHEMBL123881 0.83 20/20
SCHEMBL105916 SCHEMBL105916 0.82 20/20
SCHEMBL103964 SCHEMBL103964 0.81 20/20

Clinical trials — most relevant to BTK by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL PHASE2RECRUITING
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma PHASE2COMPLETED
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies PHASE1/PHASE2RECRUITING
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) PHASE2ACTIVE_NOT_RECRUITING
Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma PHASE2COMPLETED
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma PHASE2ACTIVE_NOT_RECRUITING
Epco, Zanu, Ritux for R/R FL or MZL PHASE2RECRUITING
A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL PHASE2ACTIVE_NOT_RECRUITING
Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells PHASE2UNKNOWN
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia PHASE2COMPLETED
Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors PHASE2NOT_YET_RECRUITING
Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission PHASE2NOT_YET_RECRUITING
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia PHASE2ACTIVE_NOT_RECRUITING
Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma PHASE2COMPLETED
Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma PHASE2UNKNOWN
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia PHASE1COMPLETED
CD20 Monoclonal Antibody Combined With BTK Inhibitor for the Treatment of Refractory Immune-related Cytopenia PHASE1NOT_YET_RECRUITING
A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy PHASE1COMPLETED
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma PHASE1COMPLETED
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) PHASE1ACTIVE_NOT_RECRUITING
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers PHASE1ACTIVE_NOT_RECRUITING
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL PHASE1WITHDRAWN
Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND) nanWITHDRAWN
Current Status of BTKi Treatment for CLL/SLL in China nanRECRUITING
A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United Kingdom nanCOMPLETED
Ibrutinib Adapted to Response in Patients With CLL nanUNKNOWN
Esprit BTK Post-Approval Study nanACTIVE_NOT_RECRUITING
The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China nanNOT_YET_RECRUITING
Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program nanCOMPLETED
Covid-19 Vaccine Responsiveness in MM and Waldenstrom nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a BTK binder may also engage these)

ProteinNameSimilarity
P35991 — 1.000 P35991 →
TXK Tyrosine-protein kinase TXK 0.999 landscape →
ITK Tyrosine-protein kinase ITK/TSK 0.998 landscape →
Q8JH64 — 0.998 Q8JH64 →
BMX Cytoplasmic tyrosine-protein kinase BMX 0.996 landscape →
P42682 — 0.994 P42682 →
TEC Tyrosine-protein kinase Tec 0.994 landscape →
P24604 — 0.994 P24604 →
P97504 — 0.992 P97504 →
P41241 — 0.992 P41241 →
P00528 — 0.991 P00528 →
Q03526 — 0.991 Q03526 →
FRK Tyrosine-protein kinase FRK 0.990 landscape →
Q0VBZ0 — 0.990 Q0VBZ0 →
Q64725 — 0.989 Q64725 →
CSK Tyrosine-protein kinase CSK 0.988 landscape →
Q00655 — 0.988 Q00655 →
P32577 — 0.988 P32577 →
P42690 — 0.988 P42690 →
Q54Y55 — 0.988 Q54Y55 →
Q60629 — 0.988 Q60629 →
P41239 — 0.988 P41239 →
Q54RB7 — 0.987 Q54RB7 →
P48025 — 0.987 P48025 →
P08630 — 0.987 P08630 →
O13147 — 0.986 O13147 →
Q9V9J3 — 0.986 Q9V9J3 →
P42687 — 0.986 P42687 →
SYK Tyrosine-protein kinase SYK 0.986 landscape →
P42686 — 0.986 P42686 →